S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ADAG

Adagene (ADAG) Stock Price, News & Analysis

$2.66
+0.15 (+5.98%)
(As of 03/27/2024 ET)
Today's Range
$2.50
$2.70
50-Day Range
$2.50
$4.15
52-Week Range
$1.10
$4.38
Volume
6,186 shs
Average Volume
114,131 shs
Market Capitalization
$117.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adagene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
88.0% Upside
$5.00 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Adagene in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.15) to ($1.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.71 out of 5 stars

Medical Sector

673rd out of 939 stocks

Pharmaceutical Preparations Industry

307th out of 422 stocks

ADAG stock logo

About Adagene Stock (NASDAQ:ADAG)

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADAG Stock Price History

ADAG Stock News Headlines

Adagene (NASDAQ:ADAG) Trading Down 8.4%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
How Is The Market Feeling About Adagene?
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Morgan Stanley 'encouraged' by 2 cPRs reported by Adagene
Adagene price target lowered by 40c at Morgan Stanley, here's why
Are Medical Stocks Lagging Medpace (MEDP) This Year?
See More Headlines
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+88.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.29 million
Book Value
$1.91 per share

Miscellaneous

Free Float
34,764,000
Market Cap
$117.36 million
Optionable
Not Optionable
Beta
0.47
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Peter P. Luo Ph.D. (Age 58)
    Co- Founder, Chairman, CEO and President of R&D
  • Mr. Man Kin Tam M.B.A. (Age 47)
    CFO & Director
  • Dr. Jc Xu M.D. (Age 59)
    Ph.D., Chief Scientific Officer
  • Ms. Ami Celeste Knoefler
    Vice President of Investor Relations & Corporate Communications
  • Ms. Ling Zhou
    Head of Human Resources
  • Dr. Qinghai Zhao (Age 63)
    Chief Manufacturing Officer
  • Ms. Yan Li M.B.A. (Age 49)
    Senior VP of Bioinformatics & Information Technology and Director
  • Ms. Xiaohong She (Age 57)
    Senior VP & Head of Clinical Operations
  • Dr. Guizhong Liu Ph.D. (Age 53)
    Head of Biology & Pharmacology
  • Mr. Alexander Goergen (Age 37)
    VP & Head of Business Development

ADAG Stock Analysis - Frequently Asked Questions

Should I buy or sell Adagene stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings
or view top-rated stocks.

What is Adagene's stock price target for 2024?

1 brokers have issued 1 year price targets for Adagene's shares. Their ADAG share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 88.0% from the stock's current price.
View analysts price targets for ADAG
or view top-rated stocks among Wall Street analysts.

How have ADAG shares performed in 2024?

Adagene's stock was trading at $1.9314 at the beginning of 2024. Since then, ADAG stock has increased by 37.7% and is now trading at $2.66.
View the best growth stocks for 2024 here
.

Are investors shorting Adagene?

Adagene saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 22,300 shares, an increase of 9.9% from the February 29th total of 20,300 shares. Based on an average daily trading volume, of 107,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are sold short.
View Adagene's Short Interest
.

When is Adagene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ADAG earnings forecast
.

When did Adagene IPO?

Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager.

Who are Adagene's major shareholders?

Adagene's stock is owned by a variety of institutional and retail investors. Top institutional investors include WuXi AppTec Co. Ltd. (9.64%).

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAG) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners